期刊文献+

AGO1调节p53表达与肝细胞癌根治性切除患者预后的相关性 被引量:3

The study of AGO1 regulates p53 expression and the prognosis of patients with hepatocellular carcinoma after curative resection
原文传递
导出
摘要 目的 探讨AGO1在肝细胞癌中的表达、功能及根治性切除术后的预后价值.方法 检测不同转移潜能的肝癌细胞株HCCLM3、MHCC97L和HepG2中AGO1 mRNA和蛋白表达.利用小干扰RNA,检测AGO1表达抑制后对HCCLM3和HepG2增殖侵袭功能和p53表达的影响.在200例行根治性切除的肝细胞癌患者肿瘤组织芯片中进行免疫组织化学染色,分析AGO1表达与患者预后的关系.结果 AGO1在人肝癌细胞株HCCLM3、MHCC97L及HepG2的mRNA表达量分别为0.400±0.025、0.188 ±0.022及0.154 ±0.019,高转移潜能肝癌细胞株表达显著高于低转移潜能肝癌细胞株(P<0.05).细胞增殖、侵袭及p53表达在AGO1表达抑制后显著下降.肿瘤组织中AGO1表达与较小的年龄(P<0.05)、较高的血清甲胎蛋白(AFP)值(P<0.01)、HBeAg阳性状态(P<0.05)、肝硬化(P<0.05)、肝内或肝外复发(P<0.01)呈正相关,且为总体生存率(OS,P<0.01)和无瘤生存率(DFS,P<0.01)的独立危险因素.结论 AGO1可能提高了肝癌的增殖转移能力,且与p53通路相关.AGO1可能成为肝细胞癌的预后指标. Objective To investigate AGO1 expression,functions and prognostic value in Hepatocellular carcinoma patients underwent radical resection.Methods AGO1 expression was measured in HCCLM3,MHCC97L,and HepG2 cell lines.Using small interfering RNA,AGO1 functions and its effects on p53 were investigated in HCCLM3 and HepG2 cell lines.Immunohistochemistry in tissue microarrays consisting of 200 tumor tissue from hepatocellular carcinoma (HCC) patients underwent radical resection was used to analyze the AGO1 expression with prognosis.Results AGO1 mRNA expression in HCC cell lines HCCLM3,MHCC97L and HepG2 is 0.400 ± 0.025,0.188 ± 0.022 and 0.154 ± 0.019,increased in parallel with the metastatic potential of the HCC cell lines (P 〈 0.05).Cell proliferation,invasion,and p53 expression significantly decreased after AGO1 depletion in the HCC cell lines.Intratumoral AGO1 was correlated with younger age (P 〈 0.05),higher α-fetoprotein (P 〈 0.01),HBeAg-positive status (P 〈0.05),liver cirrhosis (P 〈 0.05),intrahepatic and extrahepatic recurrence (P 〈 0.01),and was an independent risk factor for overall survival (P 〈 0.01) and recurrence-free survival (P 〈 0.01).Conclusion These findings indicate that AGO1 may promote HCC proliferation and metastasis through the P53 pathways,and AGO1 may be a reliable prognostic factor in HCC patients after resection.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2014年第10期2094-2097,共4页 Chinese Journal of Experimental Surgery
基金 国家自然科学基金资助项目(81372314)
关键词 AGO1 肝细胞癌 预后 P53 AGO1 Hepatocellular carcinoma Prognosis p53
  • 相关文献

参考文献3

二级参考文献46

  • 1茅幼霞,陈迟,刘景丰.携带反义甲胎蛋白增强子/单纯疱疹病毒胸苷激酶基因的产病毒细胞系的建立及对肝癌细胞的靶向杀伤效应[J].中华实验外科杂志,2005,22(8):944-946. 被引量:3
  • 2潘卫兵,张青汉,余毅恺,叶绪龙,董能本,Toshikazu Nakamura.不同组织类型和分化程度膀胱癌患者血清肝细胞生长因子及其肿瘤组织c-met的表达差异[J].中华实验外科杂志,2006,23(10):1177-1178. 被引量:5
  • 3Miyoshi K, Tsukatmo H, Nagami T, Siomi H, Siomi MC. Slicer function of Drosophila Argonautes and its involvement in RISC formation. Genes Dev 2005; 19:2837-2848.
  • 4Leuschner PJ, Ameres SL, Kueng S, Martinez J. Cleavage of the siRNA passenger strand during RISC assembly in human cells. EMBO Rep 2006; 7:314- 320.
  • 5Matranga C, Tomari Y, Shin C, Bartel DP, Zamore PD. Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell 2005; 123:607-620.
  • 6Rand TA, Petersen S, Du F, Wang X. Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation. Cell 2005; 123:621-629.
  • 7Cifuentes D, Xue H, Taylor DW, et al. A novel miRNA processing pathway independent of Dicer requires Argonaute2 catalytic activity. Science 2010 May 6. doi: 10.1126/science. 1190809.
  • 8Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009; 11:228-234.
  • 9Hutvagner G, Simard MJ. Argonaute proteins: key players in RNA silencing. Nat Rev Mol Cell Biol 2008; 9:22-32.
  • 10Liu J, Carmell MA, Rivas FV, et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science 2004; 305:1437-1441.

共引文献9

同被引文献24

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部